Unified Patent Court (UPC) analytics are now available. Check here

EP2269603

NOVARTIS
Application Number
EP10174983A
Filing Date
Feb 18, 2002
Status
Revoked
Nov 15, 2019
Grant Date
May 20, 2015
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Biblio Summary

The patent EP2269603B1 was granted on May 20, 2015 by Novartis The patent is currently Revoked.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ZENTIVA FRANCEJul 8, 2019INTERVENTION ADMISSIBLE
ACTAVIS PTC EHFFeb 22, 2016ADMISSIBLE
INTAS PHARMACEUTICALSFeb 22, 2016ADMISSIBLE
STADA ARZNEIMITTELFeb 22, 2016ADMISSIBLE
SYNTHONFeb 22, 2016ADMISSIBLE
WITTKOPPFeb 22, 2016ADMISSIBLE
ETHYPHARMFeb 19, 2016ADMISSIBLE
GENERICS UKFeb 19, 2016ADMISSIBLE
TEVA PHARMACEUTICALSFeb 18, 2016ADMISSIBLE

Patent citations in opposition refer to prior patents or publications that may challenge the validity of a contested patent. These references help assess whether the invention is truly novel or overlaps with existing intellectual property.

Citation PhasePatent NumberPatent LinkCited Text
OppositionWO9747317
N/A
OppositionGB2177700
N/A
OppositionWO9409010
N/A
OppositionWO0069467
N/A
OppositionWO9706793
N/A
OppositionWO0145740
N/A

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.